On November 17, 2020 Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, reported that results from a prospective study using Target Selector testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS) on December 9, 2020 (Press release, Biocept, NOV 17, 2020, View Source [SID1234571294]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vered Stearns, M.D., professor of oncology, breast cancer research chair in oncology, and director of the Women’s Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns Hopkins Kimmel Cancer Center, will present "HER2 expression in matched metastatic tumor and circulating tumor cells (CTCs) in breast cancer: implications for profiling and monitoring of HER2 status to help guide anti-HER2 therapy." Following Dr. Stearns’ presentation, Biocept plans to announce the study results and to post the presentation here.
Despite improvements in early detection, one in eight women in the U.S. (12%) will develop invasive breast cancer over the course of her lifetime. Approximately 20% of breast cancers test positive for the HER2 protein and, during treatment and with disease progression, the HER2 receptor may convert from positive to negative.
"Once breast cancer metastasizes, it may be difficult to access multiple metastatic sites or to perform serial tissue biopsies to determine whether HER2 conversion has occurred," said Dr. Steans. "This prospective study was designed to evaluate the use of liquid biopsy compared with tissue biopsy for analysis of HER2 status over time."
"The ability to monitor changes in tumor alterations can provide critical information for physicians in reassessing options over the course of treating patients with metastatic breast cancer," said Michael Nall, President and CEO of Biocept. "We believe that our Target Selector is among the most sensitive blood-based tests for identifying HER2 amplification. It is highly gratifying to conduct this study with Dr. Stearns, a recognized leader in breast cancer research, and to have these results presented at the SABCS."
About SABCS
Since 1977 the San Antonio Breast Cancer Symposium (SABCS) has been the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer. Founded, owned, and operated by UT Health San Antonio, the symposium has grown to a five-day event attended by an international audience of academic investigators and private physicians from over 80 countries to attain information through abstract presentations, panel discussions, research findings, and state-of-the-art educational sessions. UT Health San Antonio, the American Association for Cancer Research (AACR) (Free AACR Whitepaper), and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine support SABCS, which provides education and accessibility to the latest information regarding the prevention, diagnosis, and treatment of premalignant breast cancer and breast disease. For more information about the symposium, please visit www.sabcs.org.